



## **A.P. Pharma to Hold APF530 Phase 2 Results Conference Call Today at 11:00 a.m. Eastern Time**

October 4, 2005

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 4, 2005--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, will hold an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Tuesday, October 4, 2005.

Management will host the call to elaborate on results from its APF530 Phase 2 clinical trial. In a press release issued on Thursday, September 29, 2005, the Company reported that all clinical endpoints in the Phase 2 study for APF530 were achieved and results support advancement of APF530 into pivotal clinical trials.

To participate on the live call by telephone, please dial 888-803-8275 from the U.S. or 706-634-1287 from outside the U.S. A telephone replay will be available for 48 hours by dialing 800-642-1687 from the U.S. or 706-645-9291 from outside the U.S., and entering reservation number 9996953.

Individuals interested in listening to the conference call via the Internet may do so by visiting [www.appharma.com](http://www.appharma.com). A replay will be available on the Company's Web site for 30 days.

### **About A.P. Pharma**

A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The Company's primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer(TM). Initial target areas of application for the Company's drug delivery technology include anti-nausea, pain management, inflammation and ophthalmic applications. The Company's product development programs are funded by the sale of common stock in June 2004, royalties from topical products currently marketed by pharmaceutical partners, proceeds from the divestitures of its cosmeceutical and analytical standards product lines and by fees it receives from collaborative partners. For further information visit the Company's Web site at [www.appharma.com](http://www.appharma.com).

### **CONTACT:**

A.P. Pharma, Inc.  
Gordon Sangster, 650-366-2626  
Chief Financial Officer

or

Investor Relations Contacts:  
Lippert/Heilshorn & Associates  
Zachary Bryant, Jody Cain, Bruce Voss  
310-691-7100  
[zbryant@lhai.com](mailto:zbryant@lhai.com) / [jcain@lhai.com](mailto:jcain@lhai.com) / [bvoss@lhai.com](mailto:bvoss@lhai.com)

### **SOURCE:**

A.P. Pharma, Inc.